Survivors of childhood cancers who were treated with anthracyclines are at increased risk for developing breast cancer.
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”
Can healthy immune cells from a patient be frozen and used in the future to make adoptive cell therapies in the event of a cancer diagnosis?
The combination of ENCO and BINI had greater antitumor activity against mCRC cells with the BRAF V600E mutation.
Patients treated with ADT for prostate cancer had a higher hazard ratio for developing Alzheimer disease than those who did not receive this therapy.
Are patients who have received fewer prior medications better candidates for the receipt of CAR-T therapies?
A close-up look at the cost of cancer care, current legislative actions, and tools clinicians can use to help ease patients’ financial burden.
A new study has suggested disrupted glucose metabolism is linked to high levels of DNA damage in the pancreas, which may contribute to the acquisition of KRAS mutations and subsequent carcinogenesis.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking.
Oncologists lacking long-term data now have more information on relapse rates and the role of obesity in treatment success.
Genomic profiling reveals the prevalence of various actionable mutations in advanced prostate cancer.
Interpreting PET scores according to established criteria is crucial for guiding treatment following initial chemotherapy in early-stage disease.